Cargando…

Micronized purified flavonoid fraction for the treatment of chronic venous insufficiency, with a focus on postthrombotic syndrome: A narrative review

INTRODUCTION: Postthrombotic syndrome (PTS) is a form of secondary chronic venous insufficiency (CVI) that occurs after deep vein thrombosis (DVT). Effective treatments for PTS are lacking. Micronized purified flavonoid fraction (MPFF) is a venoactive drug used in the treatment of CVI. OBJECTIVE: To...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Ke Xuan, Diendéré, Gisele, Galanaud, Jean‐Philippe, Mahjoub, Nada, Kahn, Susan R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8128666/
https://www.ncbi.nlm.nih.gov/pubmed/34027293
http://dx.doi.org/10.1002/rth2.12527
_version_ 1783694145358921728
author Li, Ke Xuan
Diendéré, Gisele
Galanaud, Jean‐Philippe
Mahjoub, Nada
Kahn, Susan R.
author_facet Li, Ke Xuan
Diendéré, Gisele
Galanaud, Jean‐Philippe
Mahjoub, Nada
Kahn, Susan R.
author_sort Li, Ke Xuan
collection PubMed
description INTRODUCTION: Postthrombotic syndrome (PTS) is a form of secondary chronic venous insufficiency (CVI) that occurs after deep vein thrombosis (DVT). Effective treatments for PTS are lacking. Micronized purified flavonoid fraction (MPFF) is a venoactive drug used in the treatment of CVI. OBJECTIVE: To determine whether MPFF is a good candidate to explore as a therapeutic agent for PTS. METHODS: We performed a narrative review in which we identified 14 systematic reviews, 33 randomized controlled trials, and 19 observational studies that discussed the use of MPFF in CVI, as well as studies that reported on the mechanistic action of MPFF in relation to the pathophysiology of PTS. RESULTS: MPFF targets a number of pathophysiologic components of PTS. Based on animal models and human studies investigating objective vascular and lymphatic measures, MPFF promotes venous recanalization after DVT, decreases venous remodeling and reflux, inhibits inflammatory processes, improves venous tone and stasis, improves lymphatic circulation, improves capillary hyperpermeability, and decreases tissue hypoxia. Furthermore, MPFF shows promise in improving clinical manifestations, quality of life, and objective venous parameters of CVI. Studies suggest good patient acceptability and tolerability with the use of MPFF in CVI. CONCLUSION: MPFF is a good candidate to explore as a potential therapy for PTS. Confirmatory high‐quality studies are still needed to reinforce the evidence supporting the use of MPFF in CVI. Double‐blind randomized controlled trials with clinical endpoints are needed to assess the clinical efficacy of MPFF in the treatment of PTS.
format Online
Article
Text
id pubmed-8128666
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-81286662021-05-21 Micronized purified flavonoid fraction for the treatment of chronic venous insufficiency, with a focus on postthrombotic syndrome: A narrative review Li, Ke Xuan Diendéré, Gisele Galanaud, Jean‐Philippe Mahjoub, Nada Kahn, Susan R. Res Pract Thromb Haemost Review Articles INTRODUCTION: Postthrombotic syndrome (PTS) is a form of secondary chronic venous insufficiency (CVI) that occurs after deep vein thrombosis (DVT). Effective treatments for PTS are lacking. Micronized purified flavonoid fraction (MPFF) is a venoactive drug used in the treatment of CVI. OBJECTIVE: To determine whether MPFF is a good candidate to explore as a therapeutic agent for PTS. METHODS: We performed a narrative review in which we identified 14 systematic reviews, 33 randomized controlled trials, and 19 observational studies that discussed the use of MPFF in CVI, as well as studies that reported on the mechanistic action of MPFF in relation to the pathophysiology of PTS. RESULTS: MPFF targets a number of pathophysiologic components of PTS. Based on animal models and human studies investigating objective vascular and lymphatic measures, MPFF promotes venous recanalization after DVT, decreases venous remodeling and reflux, inhibits inflammatory processes, improves venous tone and stasis, improves lymphatic circulation, improves capillary hyperpermeability, and decreases tissue hypoxia. Furthermore, MPFF shows promise in improving clinical manifestations, quality of life, and objective venous parameters of CVI. Studies suggest good patient acceptability and tolerability with the use of MPFF in CVI. CONCLUSION: MPFF is a good candidate to explore as a potential therapy for PTS. Confirmatory high‐quality studies are still needed to reinforce the evidence supporting the use of MPFF in CVI. Double‐blind randomized controlled trials with clinical endpoints are needed to assess the clinical efficacy of MPFF in the treatment of PTS. John Wiley and Sons Inc. 2021-05-08 /pmc/articles/PMC8128666/ /pubmed/34027293 http://dx.doi.org/10.1002/rth2.12527 Text en © 2021 The Authors. Research and Practice in Thrombosis and Haemostasis published by Wiley Periodicals LLC on behalf of International Society on Thrombosis and Haemostasis (ISTH). https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Review Articles
Li, Ke Xuan
Diendéré, Gisele
Galanaud, Jean‐Philippe
Mahjoub, Nada
Kahn, Susan R.
Micronized purified flavonoid fraction for the treatment of chronic venous insufficiency, with a focus on postthrombotic syndrome: A narrative review
title Micronized purified flavonoid fraction for the treatment of chronic venous insufficiency, with a focus on postthrombotic syndrome: A narrative review
title_full Micronized purified flavonoid fraction for the treatment of chronic venous insufficiency, with a focus on postthrombotic syndrome: A narrative review
title_fullStr Micronized purified flavonoid fraction for the treatment of chronic venous insufficiency, with a focus on postthrombotic syndrome: A narrative review
title_full_unstemmed Micronized purified flavonoid fraction for the treatment of chronic venous insufficiency, with a focus on postthrombotic syndrome: A narrative review
title_short Micronized purified flavonoid fraction for the treatment of chronic venous insufficiency, with a focus on postthrombotic syndrome: A narrative review
title_sort micronized purified flavonoid fraction for the treatment of chronic venous insufficiency, with a focus on postthrombotic syndrome: a narrative review
topic Review Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8128666/
https://www.ncbi.nlm.nih.gov/pubmed/34027293
http://dx.doi.org/10.1002/rth2.12527
work_keys_str_mv AT likexuan micronizedpurifiedflavonoidfractionforthetreatmentofchronicvenousinsufficiencywithafocusonpostthromboticsyndromeanarrativereview
AT dienderegisele micronizedpurifiedflavonoidfractionforthetreatmentofchronicvenousinsufficiencywithafocusonpostthromboticsyndromeanarrativereview
AT galanaudjeanphilippe micronizedpurifiedflavonoidfractionforthetreatmentofchronicvenousinsufficiencywithafocusonpostthromboticsyndromeanarrativereview
AT mahjoubnada micronizedpurifiedflavonoidfractionforthetreatmentofchronicvenousinsufficiencywithafocusonpostthromboticsyndromeanarrativereview
AT kahnsusanr micronizedpurifiedflavonoidfractionforthetreatmentofchronicvenousinsufficiencywithafocusonpostthromboticsyndromeanarrativereview